Xeris Biopharma Holdings Inc expected to post a loss of 12 cents a share - Earnings Preview

Xeris Biopharma Holdings

07/05/2024 18:56

* Xeris Biopharma Holdings Inc  XERS.OQ   XERS.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 9 for the period ending January 1 0001
    * The Chicago Illinois-based  company is expected to report
a
26.0% increase in revenue to $41.815 million from $33.2 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Xeris Biopharma Holdings
Inc
is for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Xeris
Biopharma
Holdings Inc is $4.75​, above​ its last closing price of $1.90.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.10       -0.10      -0.10     Met     -2
 Jan. 1 2023   -0.12       -0.12      -0.14     Missed  22.4
 Jun. 30 2023  -0.13       -0.13      -0.14     Missed  -9.8​
 Mar. 31 2023  -0.17       -0.17      -0.12     Beat    28.4
 ​​Jan.        -0.16       -0.16      -0.10     Beat    36.5
 1 0001                                                 
 Sep. 30 2022  -0.17       -0.16      -0.16     Met     3​
 Jan. 1 0001   -0.23       -0.23      -0.19     Beat    17.4
 Mar. 31 2022  -0.26       -0.25      -0.25     Met     1.6
 This summary was machine generated May 7 at 17:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)